Second Opinion: Big Pharma’s Back At It

If at first you don’t succeed try, try again.  That’s the old adage Big Pharma is sticking with this month in a last-ditch effort to make more money on the backs of patients and taxpayers.

Here’s a quick backstory:

A look at a new report from Oliver Wyman on the Medicare Part D Donut Hole breaks down how Big Pharma’s $8.5 billion bailout will actually affect patients and taxpayers:

Here’s another way to think about it, according to the University of Pennsylvania’s Wharton School of Business, the auto bailout ultimately cost American taxpayers $9.3 billion.  A Big Pharma bailout at $8.5 billion comes in pretty close.

At a time when one in four Americans can’t afford their medication – often having to choose between paying their rent or paying for life-saving drugs – the last thing Big Pharma deserves is a bailout.

BOTTOM LINE: If Big Pharma receives this multi-billion-dollar windfall, price-gouging drug manufacturers win and patients lose.

That’s why CSRxP sent a letter to congressional leadership in November urging them to preserve the actions Congress took in the BBA of 2018 and protect seniors and taxpayers from out-of-control drug prices during the lame duck session.

Big Pharma cannot be trusted to do the right thing.  It’s up to Congress to hold the pharmaceutical industry to account. 

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.